227 related articles for article (PubMed ID: 19145444)
21. Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG).
Harding S; Khimdas S; Bonner A; Baron M; Pope J;
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S38-43. PubMed ID: 22691207
[TBL] [Abstract][Full Text] [Related]
22. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.
Merkel PA; Clements PJ; Reveille JD; Suarez-Almazor ME; Valentini G; Furst DE;
J Rheumatol; 2003 Jul; 30(7):1630-47. PubMed ID: 12858472
[TBL] [Abstract][Full Text] [Related]
23. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.
Affandi AJ; Radstake TR; Marut W
Semin Immunopathol; 2015 Sep; 37(5):475-87. PubMed ID: 26168983
[TBL] [Abstract][Full Text] [Related]
24. Interstitial lung disease in systemic sclerosis: current and future treatment.
Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
[TBL] [Abstract][Full Text] [Related]
25. An update on biomarker discovery and use in systemic sclerosis.
Matsushita T; Takehara K
Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
[TBL] [Abstract][Full Text] [Related]
26. Systemic sclerosis: An update in 2016.
Desbois AC; Cacoub P
Autoimmun Rev; 2016 May; 15(5):417-26. PubMed ID: 26802722
[TBL] [Abstract][Full Text] [Related]
27. Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.
Nagaraja V; Matucci-Cerinic M; Furst DE; Kuwana M; Allanore Y; Denton CP; Raghu G; Mclaughlin V; Rao PS; Seibold JR; Pauling JD; Whitfield ML; Khanna D
Arthritis Rheumatol; 2020 Jul; 72(7):1049-1058. PubMed ID: 32134199
[TBL] [Abstract][Full Text] [Related]
28. Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points.
Foeldvari I; Torok KS
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101688. PubMed ID: 33896752
[TBL] [Abstract][Full Text] [Related]
29. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
Yanaba K
J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic criteria, severity classification and guidelines of systemic sclerosis.
Asano Y; Jinnin M; Kawaguchi Y; Kuwana M; Goto D; Sato S; Takehara K; Hatano M; Fujimoto M; Mugii N; Ihn H
J Dermatol; 2018 Jun; 45(6):633-691. PubMed ID: 29687465
[TBL] [Abstract][Full Text] [Related]
31. Management of scleroderma in a New Zealand tertiary rheumatology centre: emphasis on pulmonary complications.
Ng K; Gow P
N Z Med J; 2007 May; 120(1254):U2537. PubMed ID: 17515941
[TBL] [Abstract][Full Text] [Related]
32. The assessment of the patient with systemic sclerosis. Introduction.
Bombardieri S; Medsger TA; Silman AJ; Valentini G
Clin Exp Rheumatol; 2003; 21(3 Suppl 29):S2-4. PubMed ID: 12889213
[No Abstract] [Full Text] [Related]
33. Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.
Tan A; Denton CP; Mikhailidis DP; Seifalian AM
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S66-74. PubMed ID: 21586221
[TBL] [Abstract][Full Text] [Related]
34. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.
Castelino FV; Varga J
Expert Rev Clin Immunol; 2013 Nov; 9(11):1077-90. PubMed ID: 24168414
[TBL] [Abstract][Full Text] [Related]
35. [Psoriatic arthritis. Treatment outcome parameters].
Märker-Hermann E; Behrens F
Z Rheumatol; 2009 Feb; 68(1):16-22. PubMed ID: 19148655
[TBL] [Abstract][Full Text] [Related]
36. Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells.
Maria ATJ; Toupet K; Maumus M; Rozier P; Vozenin MC; Le Quellec A; Jorgensen C; Noël D; Guilpain P
Front Immunol; 2018; 9():2571. PubMed ID: 30455706
[No Abstract] [Full Text] [Related]
37. [Systemic sclerosis in 2017].
Soukup T; Veleta T
Vnitr Lek; 2018; 64(2):146-154. PubMed ID: 29595279
[TBL] [Abstract][Full Text] [Related]
38. The emerging application of semi-quantitative and quantitative capillaroscopy in systemic sclerosis.
Mihai C; Smith V; Dobrota R; Gheorghiu AM; Cutolo M; Distler O
Microvasc Res; 2018 Jul; 118():113-120. PubMed ID: 29544760
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the management of juvenile systemic sclerosis.
Zulian F; Balzarin M; Birolo C
Expert Rev Clin Immunol; 2017 Apr; 13(4):361-369. PubMed ID: 27690679
[TBL] [Abstract][Full Text] [Related]
40. Systemic sclerosis: Update for oral health care providers.
Alhendi FJ; Werth VP; Sollecito TP; Stoopler ET
Spec Care Dentist; 2020 Sep; 40(5):418-430. PubMed ID: 33448431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
